BACKGROUND AND PURPOSE: @entity2269 ( @entity2269 ) is a rare, aggressive @entity5 . We report survival rates and @entity137 associated with sequential multimodality treatment including @entity1161 ( @entity1161 ). MATERIAL AND METHODS: Medical records of 32 @entity1 with @entity2269 treated at our institution were reviewed. @entity1 underwent chemotherapy, cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC), followed by @entity1161 with intensity-modulated radiation or volumetric-modulated arc therapy. RESULTS: Median overall survival (OS) was 60months. After 18months of follow-up, 20 @entity1 (62.5%) had disease recurrence and median disease-free survival (DFS) was 10months. Median time to extrahepatic abdominal failure was 19.4months. Factors affecting time to local progression included liver @entity3 at diagnosis, and an interval of greater than 5.6months between diagnosis and HIPEC or greater than 2.1months between HIPEC and @entity1161 . None of these factors altered OS. Grade 3 or higher @entity137 occurred in 84% of @entity1 . CONCLUSIONS: @entity1161 following chemotherapy, surgical cytoreduction and HIPEC is an aggressive treatment for @entity2269 @entity1 and can result in severe side effects. Our median OS of 5years is favorable compared to prior studies, despite a median DFS of only 10months, which may be due to improved salvage therapies.

Survival and @entity137 following sequential multimodality treatment including whole abdominopelvic radiotherapy for XXXX with @entity2269 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['whole abdominopelvic radiation therapy', 'WART'] @entity2269 :: ('MESH:D058405', 'Disease') :: ['Desmoplastic small round cell tumor', 'DSRCT'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity1 :: (9606,Species) :: ['patients']
